Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
ASCO’s Research Community Forum (RCF) will be hosting a free webinar on Wednesday, December 12, 2018, from 12-1 p.m. ET to share highlights from this year’s RCF Annual Meeting workshop. Participants can gain valuable, actionable resources to implement in their own research programs. Register now.
The American Medical Association’s (AMA) House of Delegates (HOD) adopted and reaffirmed ASCO-led resolutions on cancer policy priorities, including step therapy, Medicare Part B drugs, a Competitive Acquisition Program (CAP), and clinical trial access during the recent Interim Meeting of the AMA HOD. Read more. 
ASCO is expanding its geographic reach and the number of international practices certified in delivering high-quality cancer care based on its rigorous standards. The MNGHA-Cancer Center in Saudi Arabia, the first in the Middle East, joins seven other practices in Brazil, Greece, Romania, and Spain in achieving ASCO’s Quality Oncology Practice Initiative (QOPI®) Certification. Learn more.
CMS Medicare Learning Network (MLN) will be hosting a Physician Fee Schedule Final Rule: Understanding 3 Key Topics call on Monday, November 19, 2018 from 2:00 – 3:30 PM ET. The 2019 Physician Fee Schedule final rule is estimated to increase the amount of time doctors and other clinicians spend with their patients by reducing the burden of Medicare paperwork. During this call, CMS experts will briefly cover three provisions and address questions on the following:
On November 9, 2018, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Read more. 
In the latest ASCO in Action Podcast, ASCO CEO Dr. Clifford A. Hudis discusses results from the 2018 National Cancer Opinion survey.  Among the key findings, the survey shows that nearly 40% of Americans believe cancer can be cured solely through alternative therapies. Expressing concern, Dr. Hudis says research has shown the sole use of these therapies is associated with a higher mortality rate. However, he sees this as an opportunity to inform the public. “We cannot ignore this widespread belief,” he says.
On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA®, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
The Centers for Medicare & Medicaid Services (CMS) released the final rule for the Medicare Physician Fee Schedule (MPFS) and Quality Payment Program (QPP) outlining reimbursement changes for 2019. CMS estimates that the overall impact will be a one percent reimbursement cut for the hematology/oncology and radiation/oncology specialties in 2019.